Aurinia Pharmaceuticals (NASDAQ:AUPH) Trading Up 7.1% - What's Next?

Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) TSE: AUP rose 7.1% during trading on Wednesday . The company traded as high as $8.55 and last traded at $8.65. Approximately 401,424 shares changed hands during trading, a decline of 72% from the average daily volume of 1,425,489 shares. The stock had previously closed at $8.08.

Wall Street Analyst Weigh In

Separately, StockNews.com downgraded shares of Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, February 19th.

Aurinia Pharmaceuticals Trading Down 0.5 %

The firm has a market capitalization of $1.12 billion, a price-to-earnings ratio of -54.33 and a beta of 1.26. The business's 50-day simple moving average is $8.08 and its two-hundred day simple moving average is $7.89. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17.

Insider Buying and Selling at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, CEO Peter Greenleaf sold 195,593 shares of Aurinia Pharmaceuticals stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $1,564,744.00. Following the completion of the sale, the chief executive officer now directly owns 1,953,892 shares in the company, valued at $15,631,136. This trade represents a 9.10 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Greg Keenan sold 12,239 shares of Aurinia Pharmaceuticals stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $97,912.00. Following the sale, the insider now owns 161,789 shares of the company's stock, valued at approximately $1,294,312. This represents a 7.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 343,898 shares of company stock worth $2,753,094 over the last three months. Insiders own 4.30% of the company's stock.

Remove Ads

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in AUPH. Tang Capital Management LLC grew its holdings in shares of Aurinia Pharmaceuticals by 16.6% in the fourth quarter. Tang Capital Management LLC now owns 8,429,500 shares of the biotechnology company's stock valued at $75,697,000 after purchasing an additional 1,200,000 shares in the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in shares of Aurinia Pharmaceuticals in the fourth quarter valued at approximately $9,662,000. Point72 Asset Management L.P. acquired a new position in shares of Aurinia Pharmaceuticals in the fourth quarter valued at approximately $7,630,000. Lazard Asset Management LLC grew its holdings in shares of Aurinia Pharmaceuticals by 341.9% in the fourth quarter. Lazard Asset Management LLC now owns 596,389 shares of the biotechnology company's stock valued at $5,355,000 after purchasing an additional 461,430 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Aurinia Pharmaceuticals in the third quarter valued at approximately $3,330,000. Institutional investors and hedge funds own 36.83% of the company's stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.